Portfolio of quality generic and specialty products
As on March 31, 2024, we had a portfolio of 69 active¹ ANDA and New Drug Application ("NDA") products approved by the US FDA including 55 commercialized products. Our products are spread across many therapeutic areas:
| Therapy Area |
|---|
| Analgesics/Pain Management |
| CVS |
| CNS |
| Hypokalemia |
| Skeletal Muscle Relaxants |
| NRT |
| Gastrointestinal |
| Metabolic |
| Immunosuppressant |